Dare Bioscience (DARE) Cash & Equivalents (2013 - 2026)

Dare Bioscience (DARE) has 13 years of Cash & Equivalents data on file, last reported at $24.7 million in Q4 2025.

• Quarterly Cash & Equivalents rose 57.42% year-over-year to $24.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.7 million (up 57.42% YoY) and the FY2025 annual result came in at $24.7 million, up 57.42% from the prior year.
• Cash & Equivalents rose to $24.7 million in Q4 2025, from $23.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $51.7 million in Q4 2021 to a low of $3.6 million in Q1 2024.
• A 5-year average of $21.4 million and a median of $16.1 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents surged 1006.64% — and 2024, when it tumbled 81.61%.
• Tracing DARE's Cash & Equivalents over 5 years: stood at $51.7 million in 2021, then sank by 32.91% to $34.7 million in 2022, then slumped by 69.78% to $10.5 million in 2023, then jumped by 49.85% to $15.7 million in 2024, then soared by 57.42% to $24.7 million in 2025.
• The last three Cash & Equivalents figures came in at $24.7 million (Q4 2025), $23.1 million (Q3 2025), and $5.0 million (Q2 2025), per Business Quant data.